Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAT-1: Surgery Timing and Maintenance in Advanced Ovarian Cancer
NCT05200260Phase 2Recruiting
- Sponsor
- Shanghai Gynecologic Oncology Group
- Start
- Jul 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, bevacizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Shanghai Gynecologic Oncology Group. Started Jul 2022; status: recruiting.
02
Drugs
olaparibbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05200260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200260.